Article Text

other Versions

PDF
HER2 status in unusual histological variants of gastric adenocarcinomas
  1. Giuseppe Giuffrè,
  2. Antonio Ieni,
  3. Valeria Barresi,
  4. Rosario Alberto Caruso,
  5. Giovanni Tuccari
  1. Department of Human Pathology, Section of Pathological Anatomy, A.O.U. ‘Polyclinic G. Martino’, University of Messina, Messina, Italy
  1. Correspondence to Professor Giovanni Tuccari, Department of Human Pathology, Section of Pathological Anatomy, A.O.U. ‘Polyclinic G. Martino’, Via Consolare Valeria 1, 98125 Messina, Italy; tuccari{at}unime.it

Abstract

Aim To investigate HER2 status in a cohort of 109 gastric adenocarcinomas also including unusual variants, such as 14 hepatoid (HAS) and 9 mitochondrion-rich (MRC), characterised by an opposing clinical behaviour.

Methods and Results Using HercepTest (DAKO) and FISH test (pharmDx DAKO), HER2 overexpression/amplification was encountered in 23 of 109 (21.10%) of all gastric adenocarcinomas. A progressive increase in HER2 overexpression was observed moving from the poorly cohesive histotype to MRC, tubular adenocarcinomas and HAS. A statistically significant difference was found between poorly cohesive carcinomas and the others; a similar significant difference was encountered between HAS and all other variants of adenocarcinoma. HER2 overexpression was significantly associated with high grade, advanced stage, high Ki-67 labelling index value and death from gastric cancer. Multivariate analysis identified HER2 overexpression as an independent unfavourable prognostic variable for adenocarcinomas as a whole and also for the HAS variant.

Conclusions Trastuzumab has been confirmed as an additional useful therapeutic standard option for patients with HER2-positive advanced gastric cancers, and also in aggressive variants of adenocarcinomas such as HAS.

  • Carcinoma
  • CERB 2
  • colorectal cancer
  • gastric adenocarcinoma
  • gastric cancer
  • HER2 status
  • in-situ hybridisation
  • meningioma
  • neuro-oncology
  • oncology
  • prognosis
  • trastuzumab
  • unusual variants

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the local ethics committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.